देश: कनाडा
भाषा: अंग्रेज़ी
स्रोत: Health Canada
CILAZAPRIL (CILAZAPRIL MONOHYDRATE)
PHARMASCIENCE INC
C09AA08
CILAZAPRIL
5.0MG
TABLET
CILAZAPRIL (CILAZAPRIL MONOHYDRATE) 5.0MG
ORAL
100/500TAB
Prescription
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Active ingredient group (AIG) number: 0122806002; AHFS:
APPROVED
2006-06-09
_ _ _pms-CILAZAPRIL Product Monograph _ _Page 1 of 51_ PRODUCT MONOGRAPH PR PMS-CILAZAPRIL Cilazapril Tablets 1 mg, 2.5 mg, 5 mg Cilazapril (as cilazapril monohydrate) ANGIOTENSIN CONVERTING ENZYME INHIBITOR PHARMASCIENCE INC. DATE OF REVISION: 6111 Royalmount Ave., Suite 100 October 05, 2015 Montreal, Quebec H4P 2T4 www.pharmascience.com CONTROL NO.: 184138 _ _ _pms-CILAZAPRIL Product Monograph _ _Page 2 of 51_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ........................................................................ 3 INDICATIONS AND CLINICAL USE .............................................................................. 3 CONTRAINDICATIONS ................................................................................................... 4 WARNINGS AND PRECAUTIONS .................................................................................. 5 ADVERSE REACTIONS.................................................................................................. 12 DRUG INTERACTIONS .................................................................................................. 19 DOSAGE AND ADMINISTRATION .............................................................................. 23 OVERDOSAGE ................................................................................................................ 25 ACTION AND CLINICAL PHARMACOLOGY ............................................................ 26 STORAGE AND STABILITY .......................................................................................... 29 SPECIAL HANDLING INSTRUCTIONS ....................................................................... 29 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................. 30 PART II: SCIENTIFIC INFORMATION ............................................................................... 31 PHARMACEUTICAL INFORMATION................................................. पूरा दस्तावेज़ पढ़ें